

Tetrahedron: Asymmetry 11 (2000) 2809-2821

TETRAHEDRON: ASYMMETRY

Regio- and stereoselective 6-*exo-trig* radical cyclisations onto chiral perhydro-1,3-benzoxazines: synthesis of enantiopure 3-alkylpiperidines

Rafael Pedrosa,* Celia Andrés,* Juan P. Duque-Soladana and Carlos D. Rosón

Departamento de Química Orgánica, Facultad de Ciencias, Universidad de Valladolid, Dr. Mergelina s/n, 47011 Valladolid, Spain

Received 25 May 2000; accepted 8 June 2000

Abstract

Enantiopure 3-alkyl substituted piperidines are prepared by diastereoselective 6-*exo-trig* cyclisation of perhydro-1,3-benzoxazines derived from (–)-(8)-amino menthol. The diastereoselective cyclisation is promoted by tributyltin hydride, and the competitive 1,5-hydrogen migration depends on the position of the acceptor double bond and the radical site. \bigcirc 2000 Elsevier Science Ltd. All rights reserved.

1. Introduction

Radical cyclisations are a very useful methodology for ring construction from simple to polycyclic structures,^{1–3} and carbocyclic and heterocyclic compounds of a diverse size are usual targets in modern radical chemistry.^{4,5} However, synthetic applications are somewhat constrained to the generation of five-membered rings due to the well-known behaviour of 5-hexenyl radicals in terms of regioselectivity and stereoinduction during cyclisation.⁶ Formation of larger rings by radical cyclisation is a less general synthetic pathway. In fact, ring closure is slower as the ring size increases and, contrasting with 5-hexenyl radicals, secondary competitive processes, such as interor intramolecular hydrogen abstraction,⁷ ring expansion⁸ or neophyl rearrangements⁹ can appear. As a result, a loss of regio- and stereoselectivity can be expected when forming sixmembered or larger rings.

In spite of the above considerations a good choice of starting substrates may provide good results avoiding undesired by-products. Although very few examples are known, some highly stereo-selective 6-exo cyclisations have been reported in the syntheses of indolizidine and quinolizidine alkaloids using alkyl radicals.^{10–12}

^{*} Corresponding author. E-mail: pedrosa@qo.uva.es

^{0957-4166/00/\$ -} see front matter \odot 2000 Elsevier Science Ltd. All rights reserved. P11: S0957-4166(00)00230-5

As an extension of our previous approach¹³ to chiral pyrrolidines by cyclisation of 5-hexenyl radicals, and isoquinoline or benzazepine derivatives from 6-heptenyl radicals,¹⁴ we report here on the synthesis of enantiopure 3-alkyl piperidines by 6-*exo* radical ring closure on perhydro-1,3-benzoxazines used as chiral auxiliaries.

2. Results

Preparations of perhydrobenzoxazines 3a-c were accomplished in two steps from (–)-8-amino menthol 1.¹⁵ Condensation of 1 with 3-phenylselenopropionaldehyde afforded quantitatively 2 which was further alkylated with allylic bromides in the presence of potassium carbonate in refluxing acetonitrile.

The reaction of perhydrobenzoxazine **3a** with tributyltin hydride and AIBN in refluxing benzene was complete after 9 h. Crude ¹H NMR analysis showed three compounds in the ratio 32:29:39 which were assigned to **4a**, **5a** and **6a**, respectively (Table 1, entry 1). Cyclised products **4a** and **5a** were isolated by flash chromatography and characterised as 6-*exo* products (Scheme 1). Attempts to isolate **6a** led to decomposition during purification. This compound must arise from a favoured intramolecular 1,5-hydrogen abstraction in which the double bond isomerisation takes place.

 Table 1

 Radical cyclisations of perhydrobenzoxazines 3a-c

R ¹	R ²	Benzoxazine	Yield (%) ^a	Products (dr) ^b
Me	Н	3a	(51) ^c	4a (32); 5a (29); 6a (39)
Ph	Н	3b	(90)	4b (63); 5b (37)
CO ₂ Et	Н	3c	(90)	4c (63); 5c (37)

^a Numbers in parentheses refer to the total yields of isomers isolated after flash chromatography. ^bDetermined by ¹H NMR in the reaction mixture. ^c Total yield of **4a** and **5a** isolated after flash chromatography.



Scheme 1. *Reagents and conditions*: (i) PhSeCH₂CH₂CHO, CH₂Cl₂, rt, 3 h; (ii) BrCH₂CH=CR¹R², K₂CO₃, CH₃CN, reflux, 48 h; (iii) Bu₃SnH (1.5 equiv.), AIBN (0.1 equiv.), benzene, reflux, 7–9 h

Activation of the olefinic acceptor (R = Ph, CO_2Et) increased the chemical yield in cyclised products **4–5** avoiding formation of undesired non-cyclic compound **6** (Table 1, entries 2 and 3). Furthermore, an improvement in diastereoselection is encountered for cyclisation of **3b–c**.

In an effort to improve the stereoselectivity of the cyclisation we thought that a radical centre closer to the auxiliary would be beneficial. To this end, homoallyl perhydrobenzoxazine **8** was prepared by condensation of N-(3-butenyl)-8-amino menthol 7^{15} with phenylselenoacetaldehyde¹⁶ in benzene at reflux.

Reaction of **8** with Bu_3SnH and AIBN under dilute conditions yielded a mixture of three compounds in the 38:16:46 ratio (¹H NMR). Isolation by flash chromatography afforded 6-*exo* diastereomers **9** and **10** together with the unexpected reduced perhydrobenzoxazine **11** in 80% combined yield (Scheme 2).



Scheme 2. *Reagents and conditions*: (i) PhSeCH₂CHO, benzene, reflux, 3 h (70%); (ii) Bu₃SnH (1.5 equiv.), AIBN (0.1 equiv.), benzene, reflux, 7–9 h (80%)

Unfortunately, the open perhydrobenzoxazine 11, resulting from the competitive 1,5-hydrogen migration, was the major compound obtained and remarkable changes in stereodifferentiation of the radical cyclisation were not observed. Then we turned to promote the cyclisation on substrates 13a–d by changing the radical centre to the nitrogen substituent, and placing the acceptor double bond at the acetallic carbon. The cyclisation in this type of arrangement is controlled by the A-strain^{1,3} as reported for similar 5-hexenyl radical cyclisations.¹⁷

The starting benzoxazines 13a-b,d were obtained by reductive cleavage of selenylated benzoxazine 2 using borane–THF and subsequent condensation of 12 with unsaturated aldehydes in refluxing benzene. Slow addition of a solution of Bu_3SnH and AIBN in benzene to a solution of 13a-b in the same solvent, at reflux, led to a mixture of only two products 14a-b and 15a-b corresponding to the 6-*exo* diastereomers (Scheme 3, Table 2). NOESY experiments allowed the establishment of a *trans*-relationship between the acetallic proton and its adjacent proton for major diastereo-isomers 14a-d or a *cis*-relationship for the minor ones 15a-b.



Scheme 3. *Reagents and conditions*: (i) NaBH₄–BF₃OEt₂, THF, 0°C to rt, 3 h (94%); (ii) OHCCH=CR¹R², benzene, reflux, 4 h (54–80%); (iii) Bu₃SnH (1.5 equiv.), AIBN (0.1 equiv.), benzene, reflux, 7–9 h

Radical cyclisations of perhydrobenzoxazines 13a-b,d						
R ¹	R ²	Benzoxazine	Yield (%) ^a	Products (dr) ^b		
Me	Н	13a	(78)	14a (62); 15a (38)		
Ph	Н	13b	(94)	14b (59); 15b (41)		
Me	Me	13d	(40)	14d		

 Table 2

 Radical cyclisations of perhydrobenzoxazines 13a–b,d

^a Numbers in parentheses refer to the total yields of isomers isolated after flash chromatography. ^b The yields of diastereoisomers were determined after separation and purification

As expected, a single diastereomer 14d was formed in the cyclisation of 13d (Table 2, entry 3) as a result of the strong local allylic strain operating when $R^2 \neq H$, and the reduced acyclic products were not formed for 13a–d whatever the nature of groups R^1 or R^2 . The formation of the 1,5migration products from 3 and 8, and the absence of this by-product from 13, is a consequence of the concerted six-membered transition state required for these transformations. In fact, *N*-axial substituted radicals formed from 3 and 8 can easily adopt the chair-like conformations A and B required for H-migration (Scheme 4), while the radical C, formed from 13 is unable to adopt the correct conformation for the migration of the *N*,*O*-acetallic hydrogen, in contrast with dioxolane and other acetals.^{18,19}



Assuming the axial preference for the substituent at the nitrogen in all of these benzoxazines, the exact stereochemistry of major cyclisation products $4\mathbf{a}-\mathbf{c}$ and 9 can be correctly justified in terms of the proposed model for 6-heptenyl radicals,²⁰ whereas the formation of $14\mathbf{a}-\mathbf{d}$ is a consequence of the allylic strain in the radical intermediate \mathbf{C} .¹⁷

The major cyclisation stereoisomers 4a-b and 14a,b,d, after separation by flash chromatography, were transformed into enantiopure 3-alkyl piperidines in two steps (Scheme 5). Treatment of 4a-b or 14a-b,d with LiAlH₄ and AlCl₃ in THF at 0°C led to the piperidinyl menthols 16a-d in nearly quantitative yield. The menthol derivatives were converted into 3-substituted piperidines by oxidation with PCC to the corresponding piperidinyl menthones, followed by reaction with KOH in MeOH–THF. In this way, (*R*)-3-ethylpiperidine $17a^{21}$ and (*S*)-3-benzylpiperidine 17b were obtained. These products were also formed starting from 14a and 14b, respectively. In addition, diastereomer 14d provided (*S*)-3-isopropylpiperidine 17d following the same sequence.



14a, b, d

Scheme 5. *Reagents and conditions*: (i) LiAlH₄–AlCl₃, THF, 0°C, 15 min, H₂O (93–96%); (ii) PCC, CH₂Cl₂, rt, then KOH, MeOH–THF (42–72%)

For compound 4c, the configuration of the stereocentre at C-3 in the piperidine ring was assigned by transformation into piperidine 17a following the sequence depicted on Scheme 6.



Scheme 6. *Reagents and conditions*: (i) DIBALH, toluene, 0°C, 1 h, H₂O (92%); (ii) CBr₄, Ph₃P, CH₂Cl₂, 0°C, 1.5 h then Bu₃SnH, AIBN, benzene, reflux (65%); (iii) PCC, CH₂Cl₂, rt, then KOH, MeOH–THF (68%)

In summary a concise, efficient protocol to access chiral 3-alkylpiperidines is described by mild radical cyclisation.

3. Experimental

All the reactions were monitored by TLC. Preparative chromatography was performed on silica gel (230–400 mesh) by the flash technique. Melting points were measured in open capillary tubes and are uncorrected. NMR spectra were registered on Bruker AC-300 and ARX-300

spectrometers at 300 MHz (¹H) and 75 MHz (¹³C DEPT). Optical rotations were obtained from a Perkin–Elmer 241 polarimeter.

3.1. 3-Phenylselenopropionaldehyde

A solution containing diphenyldiselenide (2.0 g, 6.4 mmol) in absolute ethanol (60 mL) was treated with sodium borohydride (0.5 g, 13 mmol) in portions. Then 3-chloropropionaldehyde diethylacetal (2.0 mL, 11.4 mmol) was added at once and the mixture refluxed for 4 h. The mixture was poured into water, extracted with ether and concentrated in vacuo. The crude acetal was hydrolysed by stirring with 2N aqueous HCl solution (50 mL) for 18 h. Extractions with ether and concentration yielded a residue which was purified by flash chromatography yielding pure aldehyde (1.97 g, 81%). Yellow oil; ¹H NMR (CDCl₃): δ = 2.85 (dt, 2H, *J* = 7.0 Hz, *J* = 1.1 Hz), 3.09 (t, 2H, *J* = 7.0 Hz), 7.20–7.50 (m, 5H), 9.71 (t, 1H, *J* = 1.1 Hz). IR (liquid film, cm⁻¹): 2810, 2710, 1710. MS (EI, *m/z*): 214 (M, 34), 158 (86), 78 (100).

3.2. 2-(2'-Phenylselenoethyl)-perhydro-1,3-benzoxazine 2

A mixture of (–)-8-amino menthol 1^{15} (1.4 g, 8.4 mmol) and 3-phenylselenopropionaldehyde (1.8 g, 8.4 mmol) was stirred in dichloromethane (5 mL) at room temperature for 3 h. The solvent was removed in vacuo yielding pure benzoxazine (3.0 g, 99%). Yellow oil; ¹H NMR (CDCl₃): δ = 0.86–1.09 (m, 4H), 0.91 (d, 3H, J = 6.5 Hz), 1.03 (s, 3H), 1.04 (s, 3H), 1.25–1.42 (m, 2H), 1.68 (m, 2H), 1.84–1.97 (m, 3H), 3.00 (t, 2H, J = 7.5 Hz), 3.28 (dt, 1H, J = 4.2 Hz, J = 10.2 Hz), 4.37 (dd, 1H, J = 5.5 Hz, J = 6.1 Hz), 7.20–7.50 (m, 5H); ¹³C NMR (CDCl₃): δ = 19.7, 22.2, 23.4, 25.5, 29.8, 31.3, 34.9, 36.8, 41.6, 51.2, 51.7, 74.8, 81.9, 126.6, 128.9 (2C), 130.4, 132.5 (2C). IR (liquid film, cm⁻¹): 3280, 730, 685. Anal. calcd for C₁₉H₂₉NOSe: C, 62.28; H, 7.98; N, 3.82. Found: C, 62.53; H, 8.14; N, 4.14.

3.3. Synthesis of perhydro-1,3-benzoxazines 3a-c

General procedure. Compounds **3a–c** were prepared, as previouly described for related compounds,²² by alkylation of **2** with the corresponding allylic bromide in the presence of potassium carbonate in acetonitrile at reflux for 48 h.

3.4. N-Crotyl-2-(2'-phenylselenoethyl)-perhydro-1,3-benzoxazine 3a

Oil, 97%; ¹H NMR (CDCl₃): $\delta = 0.87-1.05$ (m, 3H), 0.91 (d, 3H, J = 6.5 Hz), 1.12 (s, 6H), 1.32– 1.55 (m, 2H), 1.56–1.70 (m, 2H), 1.62 (dd, 3H, J = 1.3 Hz, J = 3.3 Hz), 1.85 (m, 1H), 1.87–2.02 (m, 2H), 2.99 (m, 3H), 3.28 (m, 2H), 4.65 (dd, 1H, J = 4.7 Hz, J = 7.2 Hz), 5.44 (m, 2H), 7.20–7.52 (m, 5H); ¹³C NMR (CDCl₃): $\delta = 17.7$, 20.3, 22.2, 24.3, 25.0, 26.9, 31.3, 34.7, 35.0, 41.4, 44.5, 46.2, 56.9, 75.8, 86.6, 124.4, 126.5, 128.9 (2C), 130.6, 132.5 (2C), 133.3. IR (liquid film, cm⁻¹): 730, 690. MS (CI, m/z): 422 (M+1, 13), 264 (100), 236 (83). Anal. calcd for C₂₃H₃₅NOSe: C, 65.70; H, 8.39; N, 3.33. Found: C, 65.47; H, 8.52; N, 3.16.

3.5. N-Cinnamyl-2-(2'-phenylselenoethyl)-perhydro-1,3-benzoxazine 3b

Oil, 63%; $[\alpha]_D^{20} = -31.2$ (*c* 1.1, CH₂Cl₂); ¹H NMR (CDCl₃): $\delta = 0.86-1.07$ (m, 3H), 0.91 (d, 3H, J = 6.3 Hz), 1.15 (s, 3H), 1.16 (s, 3H), 1.32-1.34 (m, 2H), 1.56 (m, 1H), 1.68 (m, 1H), 1.83 (m, 2H), 1.56 (m, 2H), 1.56 (m, 2H), 1.56 (m, 2H), 1.58 (m,

1H), 1.87–2.05 (m, 2H), 2.99 (dt, 2H, J=3.0 Hz, J=7.4 Hz), 3.27–3.35 (m, 2H), 3.53 (dd, 1H, J=5.8 Hz, J=18.1 Hz), 4.71 (dd, 1H, J=4.8 Hz, J=7.3 Hz), 6.23 (dt, 1H, J=5.4 Hz, J=15.9 Hz), 6.43 (d, 1H, J=15.9 Hz), 7.17–7.56 (m, 10H); ¹³C NMR (CDCl₃): δ =20.5, 22.2, 24.4, 25.0, 26.9, 31.3, 34.7, 35.0, 41.4, 44.8, 46.4, 57.1, 75.9, 86.5, 126.1 (2C), 126.6, 126.9, 128.4 (2C), 128.9 (3C), 130.4, 132.7 (3C), 137.5. IR (liquid film, cm⁻¹): 730, 690. Anal. calcd for C₂₈H₃₇NOSe: C, 69.69; H, 7.73; N, 2.90. Found: C, 69.52; H, 7.51; N, 3.08.

3.6. N-(3-Ethoxycarbonyl-2-propenyl)-2-(2'-phenylselenoethyl)-perhydro-1,3-benzoxazine 3c

Oil, 84%; $[\alpha]_D^{20} = -27.8$ (*c* 1.2, CH₂Cl₂); ¹H NMR (CDCl₃): $\delta = 0.85-1.07$ (m, 3H), 0.90 (d, 3H, J = 6.5 Hz), 1.05 (s, 3H), 1.16 (s, 3H), 1.23–1.33 (m, 1H), 1.30 (t, 3H, J = 7.1 Hz), 1.42 (m, 1H), 1.57 (m, 1H), 1.69 (m, 1H), 1.71–1.93 (m, 3H), 2.90–3.00 (m, 2H), 3.27 (dt, 1H, J = 3.9 Hz, J = 10.6 Hz), 3.33 (dd, 1H, J = 1.9 Hz, J = 4.3 Hz), 3.50 (ddd, 1H, J = 1.8 Hz, J = 4.7 Hz, J = 19.8 Hz), 4.18 (q, 2H, J = 7.1 Hz), 4.71 (dd, 1H, J = 4.2 Hz, J = 7.7 Hz), 6.04 (dt, 1H, J = 1.5 Hz, J = 15.5 Hz), 6.98 (dt, 1H, J = 4.5 Hz, J = 15.5 Hz), 7.20–7.56 (m, 5H); ¹³C NMR (CDCl₃): $\delta = 14.2$, 20.9, 22.2, 24.3, 24.9, 26.7, 31.3, 34.5, 34.9, 41.3, 43.6, 45.9, 57.0, 60.1, 76.0, 86.1, 120.8, 126.7, 128.9 (2C), 130.2, 132.8 (2C), 151.1, 166.8. IR (liquid film, cm⁻¹): 1670, 730, 690. Anal. calcd for C₂₅H₃₇NO₃Se: C, 62.75; H, 7.79; N, 2.93. Found: C, 62.98; H, 7.92; N, 3.14.

3.7. Radical cyclisation of perhydrobenzoxazines 3a-c

General method: To a solution of the corresponding benzoxazine 3a-c (1.5 mmol) in refluxing benzene (70 mL) was injected (5–7 h, syringe pump) a solution of tributyltin hydride (0.66 mL, 2.2 mmol) and AIBN (24 mg) in benzene (25 mL). The reflux was maintained until disappearance of starting compound (TLC). Then, the solvent was removed and the residue was purified by flash chromatography on silica gel.

3.8. Compound 4a

Colourless oil, 16%; ¹H NMR (CDCl₃): δ =0.84–0.99 (m, 3H), 0.87 (t, 3H, *J*=7.6 Hz), 0.89 (d, 3H, *J*=6.3 Hz), 1.11 (s, 3H), 1.17 (s, 3H), 1.03–1.87 (m, 12H), 2.52 (t, 1H, *J*=10.2 Hz), 2.70 (d, 1H, *J*=9.1 Hz), 3.44 (dt, 1H, *J*=4.0 Hz, *J*=10.4 Hz), 4.72 (t, 1H, *J*=3.3 Hz); ¹³C NMR (CDCl₃): δ =11.4, 20.9, 22.2, 24.9, 25.1, 26.9, 27.2, 30.8, 31.3, 35.0, 37.9, 41.3, 43.7, 45.9, 56.0, 75.9, 81.7. IR (liquid film, cm⁻¹): 1450, 735, 690. Anal. calcd for C₁₇H₃₁NO: C, 76.92; H, 11.77; N, 5.28. Found: C, 77.11; H, 11.94; N, 5.43.

3.9. Compound 4b

Colourless oil, 57%; ¹H NMR (CDCl₃): δ =0.90–1.04 (m, 2H), 0.92 (d, 3H, *J*=6.6 Hz), 1.05–1.16 (m, 1H), 1.06 (s, 3H), 1.14 (s, 3H), 1.35–1.61 (m, 6H), 1.70 (m, 1H), 1.76–1.93 (m, 3H), 2.50 (dd, 1H, *J*=7.9 Hz, *J*=13.4 Hz), 2.61 (dd, 1H, *J*=6.7 Hz, *J*=13.6 Hz), 2.63 (t, 1H, *J*=3.3 Hz), 2.69 (dd, 1H, *J*=4.1 Hz, *J*=10.6 Hz), 3.45 (dt, 1H, *J*=4.1 Hz, *J*=10.6 Hz), 4.70 (t, 1H, *J*=3.3 Hz), 7.13–7.28 (m, 5H); ¹³C NMR (CDCl₃): δ =20.6, 22.3, 25.1 (2C), 26.9, 30.7, 31.3, 35.0, 38.2, 40.9, 41.4, 44.0, 46.1, 55.8, 75.8, 81.7, 125.6, 128.1 (2C), 129.0 (2C), 140.7. IR (liquid film, cm⁻¹): 1445, 740, 695. Anal. calcd for C₂₂H₃₃NO: C, 80.68; H, 10.16; N, 4.28. Found: C, 80.53; H, 10.29; N, 4.41.

3.10. Compound 4c

Colourless oil, 57%; ¹H NMR (CDCl₃): δ =0.88–1.04 (m, 2H), 0.91 (d, 3H, *J*=6.4 Hz), 1.06–1.13 (m, 1H), 1.09 (s, 3H), 1.13 (s, 3H), 1.24 (t, 3H, *J*=7.0 Hz), 1.26–1.63 (m, 7H), 1.76 (m, 1H), 1.83 (m, 1H), 1.90–2.10 (m, 1H), 2.20–2.30 (m, 2H), 2.62–2.70 (m, 2H), 3.44 (dt, 1H, *J*=4.0 Hz, *J*=10.1 Hz), 4.11 (q, 2H, *J*=7.0 Hz), 4.66 (t, 1H, *J*=3.5 Hz); ¹³C NMR (CDCl₃): δ =14.2, 19.8, 22.2, 25.0, 25.5, 26.8, 30.3, 31.3, 33.1, 34.9, 39.0, 41.2, 44.4, 45.7, 55.8, 60.2, 75.7, 81.7, 172.8. IR (liquid film, cm⁻¹): 1730, 1070, 1030. Anal. calcd for C₁₉H₃₃NO₃: C, 70.55; H, 10.28; N, 4.33. Found: C, 70.42; H, 10.41; N, 4.24.

3.11. Compound 5a

Colourless oil, 15%; ¹H NMR (CDCl₃): $\delta = 0.86-0.99$ (m, 2H), 0.89 (t, 3H, J = 7.3 Hz), 0.91 (d, 3H, J = 6.5 Hz), 0.92 (s, 3H), 1.02–1.17 (m, 1H), 1.16 (s, 3H), 1.17–1.64 (m, 8H), 1.66–1.94 (m, 5H), 2.98 (dt, 1H, J = 2.6 Hz, J = 11.3 Hz), 3.35 (dt, 1H, J = 4.3 Hz, J = 10.6 Hz), 3.90 (dd, 1H, J = 3.4 Hz, J = 9.6 Hz); ¹³C NMR (CDCl₃): $\delta = 11.3$, 11.5, 22.1, 25.0, 25.7, 27.1, 29.1, 31.1, 32.7, 34.6, 37.8, 41.4, 49.1, 49.9, 55.7, 74.1, 85.4. IR (liquid film, cm⁻¹): 1590, 730, 690. Anal. calcd for C₁₇H₃₁NO: C, 76.92; H, 11.77; N, 5.28. Found: C, 76.79; H, 11.96; N, 5.09.

3.12. Compound 5b

Colourless oil, 34%; ¹H NMR (CDCl₃): δ =0.88–1.09 (m, 3H), 0.92 (d, 3H, *J*=6.5 Hz), 0.93 (s, 3H), 1.10 (s, 3H), 1.28–1.56 (m, 4H), 1.64–1.74 (m, 3H), 1.83–1.96 (m, 4H), 2.43 (dd, 1H, *J*=7.2 Hz, *J*=13.5 Hz), 2.58 (dd, 1H, *J*=6 Hz, *J*=13.5 Hz), 3.00 (dd, 1H, *J*=2.0 Hz, *J*=8.0 Hz), 3.36 (dt, 1H, *J*=4.3 Hz, *J*=10.5), 3.96 (dd, 1H, *J*=3.5 Hz, *J*=9.4 Hz), 7.14–7.31 (m, 5H); ¹³C NMR (CDCl₃): δ =11.5, 22.1, 25.0, 25.7, 29.0, 31.1, 32.6, 34.7, 37.9, 40.8, 41.4, 49.0, 49.8, 55.7, 74.2, 85.2, 125.8, 128.1 (2C), 128.9 (2C), 140.3. IR (liquid film, cm⁻¹): 1600, 730, 697. MS (CI, *m*/*z*): 356 (M⁺+1, 13), 328 (100). Anal. calcd for C₂₂H₃₃NO: C, 80.68; H, 10.16; N, 4.28. Found: C, 80.51; H, 10.32; N, 4.46.

3.13. Compound 5c

Colourless oil, 34%; ¹H NMR (CDCl₃): δ =0.88–1.10 (m, 4H), 0.91 (d, 3H, *J*=6.5 Hz), 0.92 (s, 3H), 1.14 (s, 3H), 1.25 (t, 3H, *J*=7.1 Hz), 1.30–1.93 (m, 10H), 2.18 (m, 1H), 2.20 (m, 1H), 3.04 (dt, 1H, *J*=2.6 Hz, *J*=11.2 Hz), 3.35 (dt, 1H, *J*=4.2 Hz, *J*=10.5 Hz), 3.94 (dd, 1H, *J*=3.4 Hz, *J*=9.2 Hz), 4.1 (q, 2H, *J*=7.1 Hz); ¹³C NMR (CDCl₃): δ =11.9, 14.2, 22.0, 25.0, 25.5, 29.1, 31.0, 32.0, 33.1, 34.5, 39.0, 41.2, 48.5, 49.4, 56.0, 60.2, 74.2, 84.9, 172.3. IR (liquid film, cm⁻¹): 1630, 1170. Anal. calcd for C₁₉H₃₃NO₃: C, 70.55; H, 10.28; N, 4.33. Found: C, 70.70; H, 10.12; N, 4.45.

3.14. N-(3-Butenyl)-2-(phenylselenomethyl)-perhydro-1,3-benzoxazine 8

Condensation of *N*-(3-butenyl)-8-amino menthol 7¹⁵ (5 g, 22 mmol) with phenylselenoacetaldehyde¹⁶ (6.5 g, 33 mmol) was carried out in benzene at reflux for 24 h. Filtration on Kieselguhr and removal of the solvent afforded 6.3 g (70%) of product. Yellow oil, $[\alpha]_D^{20} = -43.7$ (*c* 1.0, CH₂Cl₂). ¹H NMR (CDCl₃): $\delta = 0.85-1.06$ (m, 3H), 0.88 (d, 3H, J = 6.4 Hz), 1.09 (s, 3H), 1.13 (s, 3H), 1.28–1.47 (m, 2H), 1.58 (m, 1H), 1.65 (m, 1H), 1.84 (m, 1H), 2.19 (q, 2H, J = 7.8 Hz), 2.53 (m, 1H), 2.76 (m, 1H), 3.08 (m, 2H), 3.41 (dt, 1H, J=4.0 Hz, J=10.5 Hz), 4.77 (dd, 1H, J=5.4 Hz, J=6.9 Hz), 4.98 (m, 2H), 5.73 (ddt, 1H, J=6.8 Hz, J=10.3 Hz, J=17.1 Hz), 7.18–07.50 (m, 5H); ¹³C NMR (CDCl₃): δ =20.3, 22.1, 25.0, 26.6, 31.2, 31.4, 34.9, 38.6, 41.1, 42.6, 45.8, 57.1, 76.2, 87.0, 115.4, 126.5, 128.9 (2C), 131.1, 132.1 (2C), 136.4. IR (liquid film, cm⁻¹): 1650, 740, 700. Anal. calcd for C₂₂H₃₃NOSe: C, 65.01; H, 8.18; N, 3.45. Found: C, 65.19; H, 8.32; N, 3.29.

3.15. Compound 9

Colourless oil, 30%; ¹H NMR (CDCl₃): δ = 0.85–0.99 (m, 2H), 0.86 (d, 3H, *J* = 6.4 Hz), 0.92 (d, 3H, *J* = 6.6 Hz), 1.01–1.15 (m, 1H), 1.12 (s, 3H), 1.20 (s, 3H), 1.20–1.32 (m, 2H), 1.34–1.59 (m, 3H), 1.70 (m, 2H), 1.80 (m, 2H), 1.90 (m, 1H), 2.79 (dt, 1H, *J* = 3.9 Hz, *J* = 11.5 Hz), 2.92 (dt, 1H, *J* = 2.9 Hz, *J* = 11.5 Hz), 3.46 (dt, 1H, *J* = 4.0 Hz, *J* = 10.5 Hz), 4.82 (t, 1H, *J* = 3.0 Hz); ¹³C NMR (CDCl₃): δ = 21.3, 21.6, 22.2, 24.6, 25.1, 27.1, 31.3, 34.3, 35.0, 39.5, 39.8, 41.3, 43.5, 55.0, 76.0, 81.8. IR (liquid film, cm⁻¹): 1460, 975. MS (CI, *m*/*z*): 252 (M⁺+1, 100), 177 (40), 131 (22). Anal calcd for C₁₆H₂₉NO: C, 76.44; H, 11.63; N, 5.57. Found: C, 76.71; H, 11.74; N, 5.49.

3.16. Compound 10

White solid, 13%, mp 68–70°C (hexane); ¹H NMR (CDCl₃): δ =0.87–0.99 (m, 2H), 0.90 (d, 3H, *J*=2.1 Hz), 0.91 (s, 3H), 0.92 (d, 3H, *J*=1.6 Hz), 0.99–1.12 (m, 1H), 1.15 (s, 3H), 1.13–1.50 (m, 5H), 1.55–1.72 (m, 3H), 1.81–1.93 (m, 2H), 2.11 (dt, 1H, *J*=2.4 Hz, *J*=11.9 Hz), 3.00 (dt, 1H, *J*=3.3 Hz, *J*=11.5 Hz), 3.35 (dt, 1H, *J*=4.3 Hz, *J*=10.5 Hz), 3.90 (dd, 1H, *J*=3.5 Hz, *J*=9.5 Hz); ¹³C NMR (CDCl₃): δ =11.3, 21.7, 22.1, 25.0, 25.8, 29.8, 31.1, 34.1, 34.7, 41.4, 41.5, 42.6, 50.1, 55.6, 74.1, 84.7. IR (liquid film, cm⁻¹): 1445. MS (CI, *m*/*z*): 252 (M⁺+1, 80), 177 (45), 103 (100). Anal calcd for C₁₆H₂₉NO: C, 76.44; H, 11.63; N, 5.57. Found: C, 76.59; H, 11.74; N, 5.48.

3.17. N-(3'-Phenylselenopropyl)-8-amino menthol 12

To a mixture of sodium borohydride (1.65 g, 43.5 mmol) and BF₃–OEt₂ (8.9 mL, 72.5 mmol) in dry THF (100 mL), at 0°C under an Ar atmosphere, was slowly added a solution of benzoxazine **2** (10.6 g, 29.0 mmol) in THF, and the system was stirred at room temperature for 3 h. After this time, excess of methanol was added, and the solvents were eliminated under vacuum. The residue was treated with a 24% sodium hydroxide solution at reflux. Extractions with chloroform and removal of the solvent yielded 10.0 g (94%) of the titled amino menthol. Pale yellow oil, $[\alpha]_D^{20} = -14.6$ (*c* 2.0, CH₂Cl₂); ¹H NMR (CDCl₃): $\delta = 0.85-1.04$ (m, 3H), 0.90 (d, 3H, J = 6.6 Hz), 1.06 (s, 3H), 1.08 (s, 3H), 1.19–1.29 (m, 2H), 1.43 (m, 1H), 1.59–1.71 (m, 2H), 1.76–1.94 (m, 3H), 2.60–2.70 (m, 2H), 2.92 (t, 2H, J = 6.2 Hz), 3.58 (dt, 1H, J = 4.0 Hz, J = 10.5 Hz), 7.20–7.50 (m, 5H); ¹³C NMR (CDCl₃): $\delta = 21.4$, 22.1, 25.4, 25.6, 26.0, 30.7, 31.0, 34.9, 40.6, 44.4, 49.5, 56.8, 72.5, 126.8, 129.0 (2C), 129.9, 132.7 (2C). IR (liquid film, cm⁻¹): 3320, 1600, 760, 710. Anal. calcd for C₁₉H₃₁NOSe: C, 61.94; H, 8.48; N, 3.80. Found: C, 62.12; H, 8.67; N, 3.96.

3.18. N-Phenylselenopropyl-2-(1'-propenyl)-perhydro-1,3-benzoxazine 13a

Pale yelow oil, 60%; ¹H NMR (CDCl₃): δ = 0.84–1.18 (m, 3H), 0.90 (d, 3H, *J* = 6.5 Hz), 1.05 (s, 3H), 1.11 (s, 3H), 1.22–1.44 (m, 2H), 1.57–1.94 (m, 5H), 1.67 (dd, 3H, *J* = 1.5 Hz, *J* = 6.5 Hz), 2.41

(ddd, 1H, J = 5.8 Hz, J = 9.5 Hz, J = 14.9 Hz), 2.73 (ddd, 1H, J = 7.5 Hz, J = 9.1 Hz, J = 16.4 Hz), 2.82 (dt, 2H, J = 2.6 Hz, J = 7.2 Hz), 3.42 (dt, 1H, J = 4.0 Hz, J = 10.5 Hz), 4.76 (d, 1H, J = 6.5 Hz), 5.46 (ddd, 1H, J = 1.7 Hz, J = 6.4 Hz, J = 15.4 Hz), 5.79 (dq, 1H, J = 6.5 Hz, J = 15.4 Hz), 7.20–7.52 (m, 5H). IR (liquid film, cm⁻¹): 730, 690. Anal. calcd for C₂₃H₃₅NOSe: C, 65.70; H, 8.39; N, 3.33. Found: C, 65.88; H, 8.21; N, 3.51.

3.19. N-Phenylselenopropyl-2-styrylperhydro-1,3-benzoxazine 13b

Pale yellow oil, 80%; $[\alpha]_D^{20} = -37.0$ (*c* 1.0, CH₂Cl₂); ¹H NMR (CDCl₃): $\delta = 0.86-1.01$ (m, 2H), 0.94 (d, 3H, J = 6.6 Hz), 1.04–1.21 (m, 1H), 1.15 (s, 3H), 1.16 (s, 3H), 1.36–1.52 (m, 2H), 1.61–1.76 (m, 2H), 1.77–1.87 (m, 2H), 1.94 (m, 1H), 2.53 (ddd, 1H, J = 6.1 Hz, J = 8.8 Hz, J = 14.8 Hz), 2.70–2.90 (m, 3H), 3.52 (dt, 1H, J = 4.0 Hz, J = 10.5 Hz), 5.05 (d, 1H, J = 5.5 Hz), 6.17 (dd, 1H, J = 5.5 Hz, J = 16.1 Hz), 6.65 (d, 1H, J = 16.1 Hz), 7.10–7.40 (m, 10H); ¹³C NMR (CDCl₃): $\delta = 18.3$, 22.2, 25.1, 25.4, 26.7, 31.3, 33.7, 34.9, 41.3, 44.1, 46.9, 56.8, 75.4, 87.6, 126.4, 126.6, 127.6, 128.5, 128.8, 129.0, 130.6, 132.1, 132.4, 136.6. IR (liquid film, cm⁻¹): 735, 690. Anal. calcd for C₂₈H₃₇NOSe: C, 69.69; H, 7.73; N, 2.90. Found: C, 69.82; H, 7.58; N, 3.17.

3.20. N-Phenylselenopropyl-2-(2'methylpropenyl)-perhydro-1,3-benzoxazine 13d

Pale yellow oil, 54%; $[\alpha]_D^{20} = -14.9$ (*c* 1.0, CH₂Cl₂); ¹H NMR (CDCl₃): $\delta = 0.85-1.03$ (m, 2H), 0.92 (d, 3H, J = 6.5 Hz), 1.07–1.14 (m, 1H), 1.12 (s, 3H), 1.13 (s, 3H), 1.27–1.38 (m, 1H), 1.46 (m, 1H), 1.62–1.93 (m, 5H), 1.69 (d, 3H, J = 1.1 Hz), 1.70 (d, 3H, J = 1.1 Hz), 2.45 (ddd, 1H, J = 5.7 Hz, J = 9.2 Hz, J = 14.8 Hz), 2.70–2.90 (m, 3H), 3.47 (dt, 1H, J = 4.2 Hz, J = 9.4 Hz), 5.10 (d, 1H, J = 7.1 Hz), 5.22 (dt, 1H, J = 1.4 Hz, J = 7.1 Hz), 7.20–7.50 (m, 5H); ¹³C NMR (CDCl₃): $\delta = 17.3$, 18.4, 21.8, 24.7, 25.0, 25.4, 26.4, 30.9, 33.5, 34.5, 41.0, 43.6, 46.7, 56.3, 75.0, 84.0, 123.9, 126.0, 128.5, 130.4, 131.6, 136.0. IR (liquid film, cm⁻¹): 1640, 730, 690. Anal. calcd for C₂₄H₃₇NOSe: C, 66.34; H, 8.58; N, 3.22. Found: C, 66.51; H, 8.67; N, 3.09.

3.21. Compound 14a

48%; ¹H NMR (CDCl₃): δ =0.84–1.13 (m, 3H), 0.87 (t, 3H, *J*=7.4 Hz), 0.91 (d, 3H, *J*=6.5 Hz), 0.94 (s, 3H), 1.15 (s, 3H), 1.25–1.95 (m, 12H), 2.18 (dt, 1H, *J*=3.0 Hz, *J*=11.1 Hz), 2.90–3.10 (m, 1H), 3.31 (dt, 1H, *J*=4.3 Hz, *J*=10.6 Hz), 3.70 (d, 1H, *J*=7.5 Hz); ¹³C NMR (CDCl₃): δ =11.3, 12.7, 22.1, 24.5 (2C), 25.1 (2C), 26.1, 27.6, 31.1, 34.7, 41.3, 42.8, 49.0, 56.0, 74.5, 89.0. Anal. calcd for C₁₇H₃₁NO: C, 76.92; H, 11.77; N, 5.28. Found: C, 76.78; H, 11.62; N, 5.42.

3.22. Compound 14b

55%; ¹H NMR (CDCl₃): δ = 0.87–1.05 (m, 2H), 0.91 (d, 3H, *J* = 6.5 Hz), 0.92 (s, 3H), 1.07–1.20 (m, 1H), 1.15 (s, 3H), 1.25–1.72 (m, 8H), 1.84 (m, 1H), 1.91–2.01 (m, 1H), 2.20 (dt, 1H, *J*=2.5 Hz, *J*=10.7 Hz), 2.34 (dd, 1H, *J*=9.5 Hz, *J*=13.2 Hz), 2.93–3.05 (m, 1H), 3.17 (dd, 1H, *J*=4.0 Hz, *J*=13.2 Hz), 3.34 (dt, 1H, *J*=4.1 Hz, *J*=10.5 Hz), 3.77 (d, 1H, *J*=7.4 Hz), 7.13–7.28 (m, 5H); ¹³C NMR (CDCl₃): δ =13.0, 22.2, 24.5, 25.1, 26.1, 27.6, 31.2, 34.8, 38.1, 41.3, 42.8, 43.2, 49.0, 56.1, 74.5, 88.3, 125.5, 127.9 (2C), 129.4 (2C), 140.9. Anal. calcd for C₂₂H₃₃NO: C, 80.68; H, 10.16; N, 4.28. Found: C, 80.49; H, 10.29; N, 4.07.

3.23. Compound 14d

Colourless oil, 40%; ¹H NMR (CDCl₃): $\delta = 0.78$ (d, 3H, J = 6.9 Hz), 0.80–1.20 (m, 2H), 0.87 (d, 3H, J = 8.5 Hz), 0.90 (s, 6H), 0.94 (d, 3H, J = 9.2 Hz), 1.22–1.72 (m, 10H), 1.86–1.93 (m, 1H), 2.09–2.19 (m, 2H), 2.99–3.02 (m, 1H), 3.30 (dt, 1H, J = 4.2 Hz, J = 10.5 Hz), 3.87 (d, 1H, J = 8.0 Hz); ¹³C NMR (CDCl₃): $\delta = 12.8$, 13.7, 17.2, 21.1, 22.1, 25.1, 25.8, 26.8, 27.8, 31.1, 34.6, 41.2, 42.9, 46.5, 48.9, 55.0, 74.6, 86.8. Anal. calcd for C₁₈H₃₃NO: C, 77.36; H, 11.90; N, 5.01. Found: C, 77.23; H, 12.02; N, 4.89.

3.24. Compound 15a

30%; ¹H NMR (CDCl₃): $\delta = 0.87$ (t, 3H, J = 7.4 Hz), 0.91 (d, 3H, J = 6.5 Hz), 1.11 (s, 3H), 1.18 (s, 3H), 2.73 (dt, 1H, J = 4.1 Hz, J = 10.6 Hz), 2.84 (dt, 1H, J = 3.2 Hz, J = 12.2 Hz), 3.35 (dt, 1H, J = 4.0 Hz, J = 10.4 Hz), 4.62 (d, 1H, J = 1.5 Hz). Anal. calcd for C₁₇H₃₁NO: C, 76.92; H, 11.77; N, 5.28. Found: C, 76.83; H, 11.54; N, 5.37.

3.25. Compound 15b

Colourless oil, 39%; ¹H NMR (CDCl₃): δ =0.86–1.00 (m, 2H), 0.91 (d, 3H, *J*=6.3 Hz), 1.03 (s, 3H), 1.05 (s, 3H), 1.05–1.15 (m, 1H), 1.34–1.61 (m, 6H), 1.70 (m, 2H), 1.75–1.85 (m, 1H), 1.92 (m, 1H), 2.51 (dd, 1H, *J*=7.5 Hz, *J*=13.2 Hz), 2.66 (dd, 1H, *J*=8.0 Hz, *J*=13.2 Hz), 2.70–2.75 (m, 1H), 2.85 (dt, 1H, *J*=3.0 Hz, *J*=11.0 Hz), 3.25 (dt, 1H, *J*=4.0 Hz, *J*=10.4 Hz), 4.41 (d, 1H, *J*=2.7 Hz), 7.13–7.28 (m, 5H); ¹³C NMR (CDCl₃): δ =21.9, 22.5, 25.0, 25.1, 25.8, 27.5, 31.7, 35.2, 39.0, 40.0, 41.5, 43.0, 43.8, 56.2, 76.3, 83.2, 125.7, 128.0 (2C), 129.1 (2C), 141.0. IR (liquid film, cm⁻¹): 1600, 745, 695. Anal. calcd for C₂₂H₃₃NO: C, 80.68; H, 10.16; N, 4.28. Found: C, 80.57; H, 10.02; N, 4.17.

3.26. Reduction of 4a-b and 14a-d to 16a-d

General procedure. To a mixture of LiAlH₄ (0.60 g, 15.8 mmol) and AlCl₃ (0.70 g, 5.25 mmol) in anhydrous THF (40 mL) was slowly added a solution of the corresponding adduct **4a–b** or **14a–d** (3.10 mmol) in THF (20 mL), at 0°C under argon. The solution was stirred for 15 min at this temperature, and quenched by addition of H₂O. The solids were separated by filtration, and the residue was washed with EtOAc. The organic layer was dried over anhydrous MgSO₄, the solvents were eliminated in vacuo, and the residue was purified by recrystallisation or chromatography.

3.27. Compound 16a

Colourless solid, 94%, mp 55–57°C (hexane); $[\alpha]_D^{20} = -19.4$ (*c* 1.0, CH₂Cl₂); ¹H NMR (CDCl₃): $\delta = 0.72-1.04$ (m, 3H), 0.83 (t, 3H, J = 7.5 Hz), 0.88 (s, 3H), 0.90 (d, 3H, J = 6.4 Hz), 1.05–1.23 (m, 3H), 1.14 (s, 3H), 1.24–1.53 (m, 5H), 1.37 (m, 1H), 1.62 (m, 3H), 1.88 (m, 2H), 3.10 (d, 1H, J = 10.7 Hz), 3.22 (d, 1H, J = 10.7 Hz), 3.59 (dt, 1H, J = 4.0 Hz, J = 10.1 Hz), 8.70 (br. s, 1H); ¹³C NMR (CDCl₃): $\delta = 11.3$, 18.2, 20.9, 22.0, 25.6, 25.7, 27.6, 30.8, 30.9, 35.1, 39.1, 44.6, 46.5, 46.6, 51.3, 60.3, 72.2. IR (Nujol dispersion, cm⁻¹): 3120, 1180, 740.

3.28. Compound 16b

Colourless liquid, 96%; $[\alpha]_D^{20} = -19.6$ (*c* 2.0, CH₂Cl₂); ¹H NMR (CDCl₃): $\delta = 0.81-1.14$ (m, 4H), 0.87 (s, 3H), 0.89 (d, 3H, J = 6.6 Hz), 1.06 (s, 3H), 1.38–1.84 (m, 9H), 1.90–2.02 (m, 2H), 2.44 (dd, 1H, J = 6.6 Hz, J = 13.3 Hz), 2.49 (dd, 1H, J = 4.9 Hz, J = 13.3 Hz), 3.09 (m, 1H), 3.23 (m, 1H), 3.56 (dt, 1H, J = 4.3 Hz, J = 10.3 Hz), 7.00–7.30 (m, 5H); ¹³C NMR (CDCl₃): $\delta = 18.2$, 20.9, 22.1, 25.6, 25.8, 30.9, 31.1, 35.1, 39.2, 41.5, 44.6, 46.5 (2C), 51.4, 60.4, 72.2, 125.8, 128.1 (2C), 129.0 (2C), 140.0. IR (liquid film, cm⁻¹): 3125, 1180, 740.

3.29. Compound 16d

Pale yellow liquid, 93%; $[\alpha]_D^{20} = -21.0 (c 4.0, CH_2Cl_2)$; ¹H NMR (CDCl₃): $\delta = 0.73-0.99 (m, 4H)$, 0.74 (d, 3H, J = 6.6 Hz), 0.76 (d, 3H, J = 6.0 Hz), 0.77 (s, 3H), 0.78 (d, 3H, J = 6.0 Hz), 1.00 (s, 3H), 1.12-1.73 (m, 10H), 1.81 (m, 2H), 3.00 (d, 1H, J = 9.3 Hz), 3.10 (d, 1H, J = 10.7 Hz), 3.47 (dt, 1H, J = 3.9 Hz, J = 10.1 Hz), 8.70 (s, 1H); ¹³C NMR (CDCl₃): $\delta = 13.5$, 18.1, 20.1, 20.8, 21.9, 25.7, 26.9, 27.7, 30.8, 31.4, 35.0, 43.4, 44.5, 46.5 (2C), 49.2, 60.3, 72.1. IR (liquid film, cm⁻¹): 3120, 1185, 740.

3.30. Synthesis of enantiopure 3-alkyl-substituted piperidines 17a-d

The final 3-akylpiperidines were isolated by oxidation and elimination of the menthol template by succesive treatment with PCC and KOH solution in MeOH–THF, as previously described.¹⁵

3.31. (R)-3-Ethylpiperidine 17a hydrochloride²¹

Colourless solid, 70% from **16a**, mp 163–165°C (benzene); $[\alpha]_D^{20} = +3.0$ (*c* 0.8, MeOH) [lit.²¹ $[\alpha]_D = +3.2$ (*c* 1.0, EtOH)]. ¹H NMR (CDCl₃): $\delta = 0.85$ (t, 3H, J = 6.7 Hz), 0.90–1.00 (m, 1H), 1.10–1.30 (m, 2H), 1.70–2.00 (m, 4H), 2.40 (q, 1H, J = 11.8 Hz), 2.68 (q, 1H, J = 11.0 Hz), 3.35 (t, 2H, J = 13.2 Hz), 9.20 (br. s, 1H), 9.60 (br. s, 1H); ¹³C NMR (CDCl₃): $\delta = 10.5$, 22.0, 26.5, 28.4, 34.6, 44.2, 48.8.

3.32. (S)-3-Benzylpiperidine 17b

This piperidine was characterised as *N*-tosylamide. White solid, 42% from **16b**, mp 121–122°C (Et₂O); $[\alpha]_D^{20} = +71.9$ (*c* 1.0, CH₂Cl₂); ¹H NMR (CDCl₃): $\delta = 0.80-1.00$ (m, 1H), 1.50–1.75 (m, 3H), 1.80–2.00 (m, 1H), 2.14 (dd, 1H, J = 10.3 Hz, J = 10.9 Hz), 2.30–2.50 (m, 2H), 2.44 (s, 3H), 2.62 (dd, 1H, J = 6.6 Hz, J = 13.5 Hz), 3.50–3.60 (m, 2H), 7.14 (d, 2H, J = 8.1 Hz), 7.20–7.40 (m, 5H), 7.63 (d, 2H, J = 8.1 Hz); ¹³C NMR (CDCl₃): $\delta = 21.5$, 24.2, 29.5, 37.3, 40.0, 46.7, 51.5, 126.1, 127.6 (2C), 128.3 (2C), 129.0 (2C), 129.6 (2C), 133.1, 139.3, 143.3. Anal. calcd for C₁₉H₂₃NO₂S: C, 69.27; H, 7.04; N, 4.25. Found: C, 69.41; H, 7.18; N, 4.09.

3.33. (S)-3-Isopropylpiperidine 17d hydrochloride

White solid, 72% from **16d**, mp 118–119°C (acetone); $[\alpha]_D^{20} = +8.4$ (*c* 1.2, CHCl₃); ¹H NMR (CDCl₃): $\delta = 0.91$ (d, 3H, J = 4.0 Hz), 0.92 (d, 3H, J = 4.0 Hz), 1.10–1.30 (m, 1H), 1.54 (m, 1H), 1.70–2.00 (m, 4H), 2.56 (t, 1H, J = 12.3 Hz), 2.73 (dt, 1H, J = 4.0 Hz, J = 12.5 Hz), 3.43 (t, 2H, J = 9.0 Hz), 9.40 (br. s, 1H), 9.70 (br. s, 1H); ¹³ C NMR (CDCl₃): $\delta = 18.9$, 19.4, 22.2, 25.6, 30.6,

39.0, 44.1, 47.3. Anal. calcd for C₈H₁₈NCl: C, 58.86; H, 11.12; N, 8.59. Found: C, 58.64; H, 11.31; N, 8.42.

3.34. Reduction and deoxygenation of compound 4c

To a solution of diastereomer **4c** (32 mg, 0.1 mmol) in dry toluene, cooled to 0°C under an argon atmosphere, was added a solution of DIBALH (0.8 mL, 1 M in toluene) and the mixture was stirred for 1 h. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄, and the solvent was evaporated in vacuo, yielding 26 mg (92%) of **18** as a colourless oil: ¹H NMR (CDCl₃): δ =0.85–1.02 (m, 4H), 0.88 (s, 3H), 0.89 (d, 3H, *J*=6.0 Hz), 1.14 (s, 3H), 1.27 (m, 3H), 1.33–1.82 (m, 9H), 1.83–2.02 (m, 2H), 3.18 (dd, 2H, *J*=10.8 Hz, *J*=25.6 Hz), 3.50–3.70 (m, 3H), 9.0 (br. s, 1H); ¹³C NMR (CDCl₃): δ =18.4, 20.9, 22.0, 25.6, 29.6, 30.9, 31.4, 34.5, 35.0, 37.7, 44.5, 46.5 (2C), 51.5, 60.2, 60.8, 72.2. This product was treated with triphenylphosphine (0.14 mmol, 36 mg) and carbon tetrabromide (0.11 mmol, 38 mg) in dichloromethane at 0°C for 1.5 h. Filtration of the mixture and solvent removal afforded an oil which was subsequently reduced with tributyltin hydride (38 mL, 0.138 mmol) and AIBN (cat.) in benzene at reflux (4 h). Acid–base workup yield pure piper-idinylmenthol **16a** (65%).

Acknowledgements

We gratefully thank the Spanish DGES (Proyect PB98-0361) for financial support and the Ministerio de Educacion y Cultura for predoctoral fellowships (J.P.D.-S. and C.D.R.).

References

- 1. Curran, D. P. In *Comprehensive Organic Synthesis*; Trost, B. M.; Fleming, I.; Schemmelhack, M. F., Eds.; Pergamon Press: Oxford, 1991; Vol. 4, 779.
- 2. Bowman, W. R.; Bridge, C. F.; Brookes, P. J. Chem. Soc., Perkin Trans. 1 2000, 1.
- 3. Jasperse, P.; Curran, D. P.; Fevig, T. L. Chem. Rev. 1991, 91, 1237.
- 4. Aldabbagh, F.; Bowman, W. R. Contemporary Organic Synthesis 1997, 261.
- 5. Rousseau, G.; Homsi, F. Chem. Soc. Rev. 1997, 26, 453.
- 6. Spellmeyer, D. C.; Houk, K. N. J. Org. Chem. 1987, 52, 959.
- 7. Beckwith, A. L. J.; Moad, G. J. Chem. Soc. Chem. Commun. 1974, 472.
- 8. Santagostino, M.; Kilburn, J. D. Tetrahedron Lett. 1995, 36, 1365.
- 9. Franz, J. A.; Barrows, R. D.; Camaioni, D. M. J. Am. Chem. Soc. 1984, 106, 3964.
- 10. Beckwith, A. L. J.; Joseph, S. P.; Mayadunne, R. T. A. J. Org. Chem. 1993, 58, 4198.
- 11. Raussou, S.; Urbain, P.; Mangeney, P.; Alexakis, A.; Platzer, N. Tetrahedron Lett. 1996, 37, 1599.
- 12. Lee, E.; Li, K. S.; Lim, J. Tetrahedron Lett. 1996, 37, 1445.
- 13. Andrés, C.; Duque-Soladana, J. P.; Iglesias, J. M.; Pedrosa, R. Tetrahedron Lett. 1996, 37, 9085.
- 14. Andrés, C.; Duque-Soladana, J. P.; Iglesias, J. M.; Pedrosa, R. Synlett 1997, 1391.
- 15. Andrés, C.; Nieto, J.; Pedrosa, R.; Vicente, M. J. Org. Chem. 1998, 63, 8570.
- 16. Petrzilka, M.; Baudat, R. Helv. Chim. Acta 1979, 62, 1406.
- 17. RajanBabu, T. V. Acc. Chem. Res. 1991, 24, 139.
- 18. Stien, D.; Samy, R.; Nouguier, R.; Crich, D.; Bertrand, M. P. J. Org. Chem. 1997, 62, 275.
- 19. Gimisis, T.; Chatgilialoglu, C. J. Org. Chem. 1996, 61, 1908.
- 20. Curran, D. P.; Porter, N. A.; Giese, B. Stereochemistry of Radical Reactions; VCH: Weinheim, 1996.
- 21. Amat, M.; Pshenichnyi, G.; Bosch, J.; Molins, E.; Miravitlles, C. Tetrahedron: Asymmetry 1996, 7, 3091.
- 22. Andrés, C.; Duque-Soladana, J. P.; Pedrosa, R. J. Org. Chem. 1999, 64, 4273.